Lourdes Felix
About Lourdes Felix
Lourdes Felix, 57, has served as an independent director of Avalon GloboCare (ALBT) since January 9, 2023. She is CEO, CFO, and director of BioCorRx, Inc., with ~30 years’ experience in capital markets, public accounting, and private sector operations; she holds a B.S. in Accounting (University of Phoenix) and is an MBA candidate at Northeastern University’s D’Amore-McKim School of Business . The Board has affirmatively determined her independence under Nasdaq and SEC rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| BioCorRx, Inc. | Chief Executive Officer, Chief Financial Officer, Director | October 2012 – present | Finance, SEC/SOX compliance, operations; manages regulatory filings |
| BioCorRx Pharmaceuticals Inc. (majority-owned subsidiary) | Founder and President | Not disclosed (active during BioCorRx tenure) | Leadership in subsidiary strategy and operations |
| Private sector & public accounting | Various finance/accounting roles | Prior to October 2012 | GAAP, SEC, SOX, budgeting, controls |
External Roles
| Company | Public/Private | Role | Committee Roles |
|---|---|---|---|
| BioCorRx, Inc. | Public | CEO, CFO, Director | Not disclosed in ALBT filings |
Board Governance
- Independence: Determined independent (Felix, Sanders, Stilley, Troy) per Nasdaq and SEC criteria .
- Committees:
- Compensation Committee: Chair; members Felix, Sanders, Troy; met 2 times in FY2024; charter posted online .
- Audit Committee: Members Stilley (Chair), Sanders, Troy; met 4 times in FY2024; reviews related-party transactions and controls; charter posted online .
- Nominating & Corporate Governance Committee: Members Sanders (Chair), Stilley, Troy; met 1 time in FY2024; charter posted online .
- Attendance: Board met 5 times in 2024; each director attended at least 75% of Board and committee meetings during service period .
- Shareholder support: At the Oct. 7, 2024 annual meeting, Felix received 6,852,278 For and 78,834 Withheld votes (broker non-votes: 2,429,505); each nominee elected .
Fixed Compensation
| Metric | FY2023 | FY2024 |
|---|---|---|
| Fees Earned or Paid in Cash ($) | 68,488 | 70,000 |
| Meeting Fees | Not disclosed | Not disclosed |
| Committee Chair Fees | Included in cash total (not itemized) | Included in cash total (not itemized) |
Performance Compensation
| Metric | FY2023 | FY2024 |
|---|---|---|
| Option Awards ($ fair value) | 23,268 | 2,697 |
| Options Vested (count) | 7,803 | 533 |
| RSUs/PSUs | Not disclosed | Not disclosed |
| Performance Metrics (TSR/EBITDA/Revenue) | Not disclosed | Not disclosed |
| Clawback Policy Applicability | Company adopted clawback policy; equity awards subject to recoupment (Plan amended Aug. 29, 2023; Clawback Policy adopted Nov. 16, 2023) | Company clawback policy applies |
Note: Director compensation is primarily cash retainers and option awards; no director-specific performance metrics disclosed .
Other Directorships & Interlocks
| Individual | External Board/Role | Potential Interlock/Exposure |
|---|---|---|
| Lourdes Felix | BioCorRx, Inc. (CEO/CFO/Director) | No related-party transactions disclosed involving Felix/BioCorRx with ALBT in FY2023–FY2024; related-party items involve Chairman Wenzhao Lu and Director Tauzin; Audit Committee reviews related-party transactions . |
Expertise & Qualifications
- Corporate finance, accounting, GAAP, SEC reporting, SOX compliance; budgeting and internal controls .
- Executive leadership across finance and operations; extensive experience managing SEC filings and financial operations .
- Education: B.S. Accounting (University of Phoenix); MBA candidate (Northeastern University) .
Equity Ownership
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Common Stock Beneficially Owned (shares) | 5,803 | 13,803 | 1,586 |
| % of Common Stock Outstanding | <1% | <1% (based on 15,984,185 shares) | <1% (based on 4,252,009 shares) |
| Options/Warrants Included (60-day exercisable) | Included per SEC rules | Included per SEC rules | Included per SEC rules |
| Pledged Shares | Not disclosed | Not disclosed | Not disclosed |
| Hedging/Pledging Policy | Anti-hedging policy prohibits hedging/monetization transactions; no explicit anti-pledging policy disclosed |
Governance Assessment
- Strengths
- Independent director; chairs Compensation Committee; committee structure and charters in place; active committee cadence (Audit 4x, Comp 2x, Nominating 1x) supports oversight .
- Attendance threshold met (≥75% for Board and committees); indicates engagement .
- Shareholder support strong in 2024 (6.85M For vs 78.8k Withheld for Felix), suggesting investor confidence in the slate .
- Company-level governance protections: insider trading policy, anti-hedging, indemnification, and clawback applicable to equity awards .
- Watch items / potential risks
- Low “skin-in-the-game”: beneficial ownership <1% in each period; FY2025 holding 1,586 shares is modest relative to outstanding shares, which may limit alignment optics .
- Dual executive responsibilities at BioCorRx (CEO/CFO) may pose time/attention constraints; however, ALBT Board affirms independence and no related-party transactions involving Felix were disclosed .
- Related-party exposure exists at ALBT (Chairman Lu financing and real estate/transaction agreements; consulting with Director Tauzin/son), which the Audit Committee reviews—ongoing oversight remains important .
Appendix: Committee Activity & Policies
| Committee/Policy | FY2023 | FY2024 |
|---|---|---|
| Audit Committee Meetings | 4 | 4 |
| Compensation Committee Meetings | Not disclosed | 2 |
| Nominating & Governance Meetings | Not disclosed | 1 |
| Board Meetings | 3 | 5 |
| Anti-Hedging Policy | In place | In place |
| Clawback Policy (equity plan) | Adopted Nov. 16, 2023; applies to awards | Applies to awards |
Say-on-Pay Context (Company-Level)
| Item | 2024 Annual Meeting Vote Counts |
|---|---|
| Advisory vote on executive compensation (Say-on-Pay) | For: 6,821,344; Against: 107,329; Abstain: 2,439; Broker non-votes: 2,429,505 |
Section 16 compliance: ALBT states directors, officers, and 10% holders timely filed Forms 3/4/5 for FY2024, indicating procedural compliance .